Skip to content

Ketamine: all studies

Page 113 of 448: studies 1,121 to 1,130 of 4,475, newest first. Back to the ketamine overview

Research

Genetic ablation of the isoform γ of PI3K decreases antidepressant efficacy of ketamine in male mice.

IBRO Neuroscience Reports December 1, 2024 Gabriela N Vaz, Flávia C Turcato, Isabel A V Lima et al.

About one-third of major depressive disorder (MDD) patients demonstrate unresponsiveness to classic antidepressants, and even the clinical efficacy of fast-acting drugs such as ketamine varies significantly among patients with treatment-resistant depression. Nevertheless, the lack of suitable animal models that mimic a possible ketamine-resistant phenotype challenges the understanding of...

The antipsychotic potential of Salix Mucronata on ketamine-induced rats.

IBRO Neuroscience Reports December 1, 2024 Ntombifuthi P Ngubane, Musa V Mabandla, Brenda Z De Gama 3 citations

Salix mucronata is one of the herbal plants offered by the traditional health practitioners in KwaZulu-Natal, South Africa for the treatment of schizophrenia. This study aimed to investigate the effects of repeated administration of ketamine on social interaction, novelty and motivation in adult, male Sprague Dawley rats. It also aimed to investigate the potential of risperidone and the herbal...

DOI: 10.1016/j.ibneur.2024.06.003 (opens in new tab) Full text (opens in new tab) Herbal medicine Mental disorders Risperidone Salix mucronata +4

Comparing the hemodynamic effects of ketamine versus fentanyl bolus in patients with septic shock: a randomized controlled trial.

Journal of Anesthesia December 1, 2024 Maha Mostafa, Ahmed Hasanin, Basant Reda et al. 5 citations

Ketamine and fentanyl are commonly used for sedation and induction of anesthesia in critically ill patients. This study aimed to compare the hemodynamic effects of ketamine versus fentanyl bolus in patients with septic shock. This randomized controlled trial included mechanically ventilated adults with septic shock receiving sedation. Patients were randomized to receive either 1 mg/kg ketamine...

Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment.

Pharmacological Reports December 1, 2024 Aleksander Kwaśny, Wiesław Jerzy Cubała, Adam Włodarczyk et al. 2 citations

This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administration. This is a post-hoc analysis of a naturalistic observational study, which enrolled 28 inpatients with treatment-resistant major depressive disorder and analyzed self-reported sleep changes (items 1-4; 'insomnia', 'nighttime restlessness', 'early...

Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.

Psychiatry and Clinical Neurosciences December 1, 2024 Yohei Ohtani, Hideaki Tani, Kie Nomoto-Takahashi et al. 13 citations

Although the antidepressant effect of ketamine on treatment-resistant depression (TRD) has been frequently reported in North American and European countries, evidence is scarce among the Asian population. We aimed to evaluate the efficacy and safety of intravenous ketamine in Japanese patients with TRD. In this double-blind randomized placebo-controlled trial, 34 Japanese patients with TRD were...

The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder.

Pharmacological Reports December 1, 2024 Julia Kwaśna, Wiesław Jerzy Cubała, Aleksander Kwaśny et al. 4 citations

Emerging evidence indicates that intravenous ketamine is effective in managing treatment-resistant unipolar and bipolar depression. Clinical studies highlight its favorable efficacy, safety, and tolerability profile within a dosage range of 0.5-1.0 mg/kg based on actual body weight. However, data on alternative dosage calculation methods, particularly in relation to body mass index (BMI) and...

Serotonergic transmission plays differentiated roles in the rapid and sustained antidepressant-like effects of ketamine.

British Journal of Pharmacology December 1, 2024 Yong-Yu Yin, Jiao-Zhao Yan, Qian-Qian Wei et al. 13 citations

The emerging antidepressant effects of ketamine have inspired tremendous interest in its underlying neurobiological mechanisms, although the involvement of 5-HT in the antidepressant effects of ketamine remains unclear. The chronic restraint stress procedure was performed to induce depression-like behaviours in mice. OFT, FST, TST, and NSFT tests were used to evaluate the antidepressant-like...

Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.

Neuropsychopharmacology December 1, 2024 Charalampos Brakatselos, Alexia Polissidis, George Ntoulas et al. 10 citations

Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been...

DOI: 10.1038/s41386-024-01977-1 (opens in new tab) Full text (opens in new tab) CBD Schizophrenia treatment Brain research Psychiatric medicine

Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration.

Drugs - real world outcomes December 1, 2024 Michał Pastuszak, Wiesław Jerzy Cubała, Aleksander Kwaśny 3 citations

Residual symptoms are frequently observed in a significant number of patients with depression, indicating an unmet need for effective management strategies to achieve functional recovery. This observational study aimed to evaluate the impact of ketamine infusions on depressive symptoms in patients with bipolar disorder who continued their baseline psychotropic and chronic somatic treatments....

DOI: 10.1007/s40801-024-00453-y (opens in new tab) Full text (opens in new tab) Ketamine therapy Bipolar depression Treatment resistance Psychiatric medicine +1

Abnormal resting-state functional connectivity of the right anterior cingulate cortex in chronic ketamine users and its correlation with cognitive impairments.

Asian Journal of Psychiatry December 1, 2024 Jun Zhong, Fengchun Wu, Huawang Wu et al. 1 citation

Chronic ketamine use leads to cognitive impairments, however, the neural mechanisms underpinning these impairments are still unclear. Many studies showed Anterior cingulate cortex (ACC)is strongly involved in cognition and drug addiction, as supported by our previous studies. The objective of this study was to assess the variations in resting-state functional connectivity (FC) changes in the...

DOI: 10.1016/j.ajp.2024.104199 (opens in new tab) Full text (opens in new tab) Chronic ketamine use Cognitive impairments Functional connectivity Brain connectivity +3